Neelima Kethineni, MD
Infectious Disease · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kethineni’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A90570 · Current
Licensed to practise in California · since 2005 · expires 2028-06-30 · Andhra University, Rangaraya Medical College Aka University of Health Sciences Vijayawada.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$32,980
Medicare paid this office $32,980 for 178 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $12,605 | $114 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 74 | $9,168 | $121 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $6,760 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,161 | $72 |
| Short return visit (20+ min) | 11 | $661 | $51 |
See all 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $12,605 | $114 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 74 | $9,168 | $121 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $6,760 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,161 | $72 |
| Short return visit (20+ min) | 11 | $661 | $51 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $615 | $31 |
Who their Medicare patients are
178 Original Medicare patients in 2024. Average age 70 · Under 65 26% · 85 and older 13% · Women 44% · Also on Medicaid 79% · Health risk score 3.08. Above the middle of the specialty; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Diabetes 61% · Chronic kidney disease 54% · Heart failure 46% · Depression 35% · Coronary heart disease 31% · Atrial fibrillation 28% · COPD 26% · Stroke 18% · Cancer 17% · Dementia 17%.
The office billed $116,000, Medicare allowed $41,857 and paid $32,980; for 313 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 178 | 313 | 70 | 3.08 | $116,000 | $32,980 |
| 2023 | 127 | 168 | 67 | 2.69 | $54,752 | $14,784 |
| 2022 | 126 | 161 | 68 | 2.28 | $56,652 | $13,693 |
| 2021 | 146 | 201 | 68 | 2.12 | $58,733 | $15,202 |
| 2020 | 150 | 208 | 65 | 2.80 | $42,192 | $13,593 |
| 2019 | 193 | 301 | 64 | 2.95 | $56,879 | $17,161 |
| 2018 | 165 | 305 | 63 | 2.81 | $52,275 | $20,337 |
| 2017 | 194 | 355 | 62 | 2.81 | $58,914 | $23,406 |
| 2016 | 191 | 450 | 61 | 2.51 | $66,545 | $28,540 |
| 2015 | 216 | 502 | 64 | 2.57 | $78,379 | $37,295 |
| 2014 | 169 | 416 | 61 | 2.66 | $60,220 | $30,868 |
| 2013 | 183 | 480 | 63 | 2.63 | $62,481 | $30,587 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $7,496 | $141 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 42 | $4,869 | $106 |
| Short return visit (20+ min) | 20 | $958 | $37 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $183 | $14 |
2022: 4 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 49 | $5,559 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,910 | $158 |
| Short return visit (20+ min) | 25 | $1,261 | $43 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $229 | $18 |
2021: 5 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 71 | $8,393 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,769 | $163 |
| Short return visit (20+ min) | 24 | $1,168 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $934 | $58 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $327 | $12 |
2020: 7 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,766 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,692 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $2,131 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,466 | $86 |
| Short return visit (20+ min) | 34 | $1,054 | $26 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $302 | $18 |
| Telephone medical discussion with physician, 5-10 minutes | 15 | $179 | $11 |
2019: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 109 | $8,053 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $3,904 | $83 |
| Short return visit (20+ min) | 51 | $2,136 | $33 |
| New patient visit (30+ min) | 21 | $1,252 | $60 |
| Return visit (30+ min) | 11 | $660 | $55 |
2018: 3 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 91 | $11,335 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $4,354 | $57 |
| Short return visit (20+ min) | 60 | $2,752 | $32 |
2017: 6 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 106 | $11,871 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,087 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $2,624 | $80 |
| Short return visit (20+ min) | 56 | $2,515 | $30 |
| Return visit (30+ min) | 23 | $1,528 | $49 |
| Short return visit | 11 | $290 | $18 |
2016: 6 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 83 | $10,317 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $6,400 | $56 |
| Return visit (30+ min) | 63 | $3,773 | $48 |
| Short return visit (20+ min) | 68 | $3,409 | $33 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $2,266 | $81 |
| New patient visit (45+ min) | 17 | $1,313 | $77 |
2015: 6 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 120 | $15,001 | $108 |
| Return visit (30+ min) | 77 | $6,113 | $51 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $5,402 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $4,616 | $58 |
| Short return visit (20+ min) | 42 | $2,133 | $36 |
| New patient visit (45+ min) | 19 | $1,671 | $88 |
2014: 7 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 57 | $6,755 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,211 | $163 |
| Return visit (30+ min) | 51 | $5,487 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $4,020 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $4,010 | $55 |
| Short return visit (20+ min) | 38 | $2,214 | $34 |
| New patient visit (45+ min) | 13 | $1,236 | $95 |
2013: 7 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 95 | $11,933 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $5,645 | $56 |
| Return visit (30+ min) | 45 | $5,150 | $55 |
| Short return visit (20+ min) | 56 | $2,834 | $34 |
| New patient visit (45+ min) | 17 | $1,632 | $96 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $1,321 | $31 |
| New patient visit (30+ min) | 11 | $537 | $49 |
Medicaid work
$10,663 in 2024
Medicaid paid $10,663 for 146 billed services this clinician did in 2024, up to 32 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 146 | $10,663 |
| 2024 | 146 | 1 | 32 | $10,663 |
| 2023 | 293 | 3 | 31 | $19,515 |
| 2022 | 110 | 1 | 22 | $8,011 |
| 2021 | 235 | 4 | 31 | $14,472 |
| 2020 | 211 | 3 | 24 | $14,476 |
| 2019 | 427 | 2 | 29 | $23,664 |
| 2018 | 547 | 4 | 34 | $28,451 |
See the largest Medicaid services in earlier years
2023
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 262 | $18,815 |
| Short return visit (20+ min) | 16 | $579 |
| 1ST HOSP IP/OBS HIGH 75 | 15 | $120 |
2022
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 110 | $8,011 |
2021
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 158 | $11,469 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 26 | $1,049 |
| IP/OBS CONSLTJ NEW/EST PT LOW MDM 45 MINUTES | 24 | $1,018 |
| Short return visit (20+ min) | 27 | $936 |
2020
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 169 | $13,294 |
| Short return visit (20+ min) | 30 | $1,080 |
| Service | 12 | $102 |
2019
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 180 | $14,692 |
| Short return visit (20+ min) | 247 | $8,972 |
2018
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 202 | $16,772 |
| Short return visit (20+ min) | 218 | $7,137 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 71 | $2,945 |
| OFF/OP EST MAY X REQ PHY/QHP | 56 | $1,597 |
Drugs they prescribed that Part D paid
$1,313,954
Pharmacies billed $1,313,954 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 536) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
173 generic and 363 brand-name prescriptions · $1,313,954 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Biktarvy | 87 | $346,286 | $3,980 |
| Dovato | 75 | $237,052 | $3,161 |
| Genvoya | 31 | $126,230 | $4,072 |
| Juluca | 35 | $122,277 | $3,494 |
| Symtuza | 20 | $91,172 | $4,559 |
See all 19 drugs
| Biktarvy | 87 | $346,286 | $3,980 |
| Dovato | 75 | $237,052 | $3,161 |
| Genvoya | 31 | $126,230 | $4,072 |
| Juluca | 35 | $122,277 | $3,494 |
| Symtuza | 20 | $91,172 | $4,559 |
| Prezcobix | 34 | $82,890 | $2,438 |
| Descovy | 37 | $80,280 | $2,170 |
| Triumeq | 18 | $66,078 | $3,671 |
| Pifeltro | 11 | $17,884 | $1,626 |
| Posaconazole | 12 | $13,078 | $1,090 |
| Nevirapine Er | 11 | $4,563 | $415 |
| Entecavir | 32 | $2,712 | $85 |
| Lamivudine-Zidovudine | 11 | $2,529 | $230 |
| Rifampin | 22 | $1,086 | $49 |
| Fluconazole | 17 | $937 | $55 |
| Itraconazole | 12 | $286 | $24 |
| Nevirapine | 11 | $275 | $25 |
| Isoniazid | 25 | $134 | $5 |
| Acyclovir | 11 | $20 | $2 |
Year by year
| 2024 | 536 | 54 | 0% (0) | 68% | $1,313,954 |
| 2023 | 607 | 59 | 0% (0) | 67% | $1,604,699 |
| 2022 | 682 | 70 | 0% (0) | 74% | $2,207,283 |
| 2021 | 727 | 77 | 0% (0) | 72% | $2,058,995 |
| 2020 | 777 | 74 | 0% (0) | 72% | $2,124,100 |
| 2019 | 898 | 84 | 0% (0) | 73% | $2,853,576 |
| 2018 | 1,139 | 77 | 0% (0) | 73% | $2,064,865 |
| 2017 | 1,351 | 89 | None | 70% | $2,228,294 |
| 2016 | 1,376 | 95 | 0% (0) | 68% | $2,680,654 |
| 2015 | 1,404 | 87 | 0% (0) | 67% | $2,556,885 |
| 2014 | 1,634 | 71 | None | 68% | $1,595,725 |
| 2013 | 1,637 | 68 | 2% (37) | 70% | $1,138,977 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Biktarvy | 89 | $372,501 | $4,185 |
| Dovato | 65 | $200,139 | $3,079 |
| Juluca | 49 | $176,276 | $3,597 |
| Genvoya | 38 | $157,764 | $4,152 |
| Symtuza | 22 | $109,774 | $4,990 |
| Triumeq | 25 | $96,476 | $3,859 |
| Prezcobix | 34 | $87,579 | $2,576 |
| Descovy | 30 | $70,288 | $2,343 |
| Posaconazole | 26 | $60,413 | $2,324 |
| Odefsey | 12 | $45,639 | $3,803 |
| Pifeltro | 17 | $31,326 | $1,843 |
| Entecavir | 25 | $5,308 | $212 |
| Lamivudine-Zidovudine | 12 | $2,764 | $230 |
| Itraconazole | 11 | $1,606 | $146 |
| Nevirapine | 12 | $305 | $25 |
| Potassium Chloride | 13 | $265 | $20 |
| Ondansetron | 13 | $208 | $16 |
| Isoniazid | 13 | $134 | $10 |
| Acyclovir | 13 | $72 | $6 |
2022: 18 drugs
| Epclusa | 21 | $553,635 | $26,364 |
| Biktarvy | 103 | $397,196 | $3,856 |
| Juluca | 72 | $242,152 | $3,363 |
| Genvoya | 62 | $238,225 | $3,842 |
| Dovato | 68 | $205,423 | $3,021 |
| Triumeq | 43 | $153,596 | $3,572 |
| Symtuza | 24 | $109,448 | $4,560 |
| Prezcobix | 45 | $108,299 | $2,407 |
| Descovy | 32 | $68,064 | $2,127 |
| Posaconazole | 15 | $35,761 | $2,384 |
| Pifeltro | 12 | $21,803 | $1,817 |
| Vemlidy | 13 | $18,311 | $1,409 |
| Nevirapine Er | 12 | $5,371 | $448 |
| Entecavir | 29 | $4,160 | $143 |
| Lamivudine-Zidovudine | 12 | $1,203 | $100 |
| Nevirapine | 12 | $567 | $47 |
| Potassium Chloride | 13 | $222 | $17 |
| Isoniazid | 11 | $89 | $8 |
2021: 20 drugs
| Epclusa | 16 | $425,894 | $26,618 |
| Genvoya | 89 | $313,732 | $3,525 |
| Biktarvy | 84 | $304,959 | $3,630 |
| Juluca | 82 | $258,310 | $3,150 |
| Triumeq | 52 | $173,924 | $3,345 |
| Prezcobix | 65 | $142,503 | $2,192 |
| Dovato | 34 | $92,643 | $2,725 |
| Symtuza | 20 | $86,734 | $4,337 |
| Descovy | 30 | $59,583 | $1,986 |
| Delstrigo | 14 | $33,977 | $2,427 |
| Posaconazole | 12 | $32,983 | $2,749 |
| Vemlidy | 23 | $29,876 | $1,299 |
| Entecavir | 39 | $15,633 | $401 |
| Lamivudine-Zidovudine | 22 | $7,870 | $358 |
| Nevirapine Er | 13 | $4,488 | $345 |
| Sulfamethoxazole-Trimethoprim | 12 | $1,627 | $136 |
| Fluconazole | 18 | $1,048 | $58 |
| Valacyclovir | 11 | $779 | $71 |
| Nevirapine | 22 | $655 | $30 |
| Rifampin | 11 | $364 | $33 |
2020: 18 drugs
| Genvoya | 109 | $363,648 | $3,336 |
| Epclusa | 13 | $336,874 | $25,913 |
| Juluca | 101 | $313,063 | $3,100 |
| Biktarvy | 83 | $280,023 | $3,374 |
| Prezcobix | 83 | $171,453 | $2,066 |
| Triumeq | 48 | $147,595 | $3,075 |
| Symtuza | 33 | $133,690 | $4,051 |
| Descovy | 23 | $43,100 | $1,874 |
| Atripla | 11 | $34,081 | $3,098 |
| Entecavir | 55 | $19,237 | $350 |
| Vemlidy | 13 | $15,775 | $1,213 |
| Lamivudine-Zidovudine | 24 | $9,442 | $393 |
| Nevirapine Er | 12 | $3,292 | $274 |
| Fluconazole | 18 | $1,960 | $109 |
| Sulfamethoxazole-Trimethoprim | 12 | $1,428 | $119 |
| Ethambutol | 13 | $1,088 | $84 |
| Azithromycin | 17 | $889 | $52 |
| Nevirapine | 24 | $385 | $16 |
2019: 25 drugs
| Epclusa | 35 | $915,672 | $26,162 |
| Genvoya | 107 | $336,379 | $3,144 |
| Juluca | 104 | $287,548 | $2,765 |
| Prezcobix | 98 | $193,496 | $1,974 |
| Biktarvy | 43 | $135,499 | $3,151 |
| Descovy | 75 | $132,336 | $1,764 |
| Triumeq | 42 | $125,965 | $2,999 |
| Tivicay | 26 | $45,743 | $1,759 |
| Atripla | 12 | $34,885 | $2,907 |
| Evotaz | 17 | $28,004 | $1,647 |
| Isentress | 16 | $23,195 | $1,450 |
| Entecavir | 49 | $21,704 | $443 |
| Kaletra | 15 | $15,609 | $1,041 |
| Vemlidy | 13 | $14,545 | $1,119 |
| Edurant | 12 | $13,567 | $1,131 |
| Voriconazole | 15 | $13,364 | $891 |
| Lamivudine-Zidovudine | 19 | $9,693 | $510 |
| Tenofovir Disoproxil | 18 | $3,871 | $215 |
| Nevirapine Er | 12 | $2,841 | $237 |
| Abacavir-Lamivudine | 16 | $2,330 | $146 |
| Dapsone | 12 | $800 | $67 |
| Azithromycin | 17 | $690 | $41 |
| Nevirapine | 17 | $436 | $26 |
| Sulfamethoxazole-Trimethoprim | 25 | $215 | $9 |
| Ibuprofen | 14 | $57 | $4 |
2018: 26 drugs
| Genvoya | 108 | $325,199 | $3,011 |
| Prezcobix | 125 | $226,460 | $1,812 |
| Descovy | 128 | $214,074 | $1,672 |
| Triumeq | 50 | $139,776 | $2,796 |
| Evotaz | 75 | $122,778 | $1,637 |
| Tivicay | 67 | $114,707 | $1,712 |
| Biktarvy | 27 | $77,294 | $2,863 |
| Isentress | 41 | $63,024 | $1,537 |
| Atripla | 19 | $52,336 | $2,755 |
| Edurant | 35 | $36,843 | $1,053 |
| Truvada | 14 | $23,073 | $1,648 |
| Entecavir | 35 | $19,924 | $569 |
| Vemlidy | 14 | $15,140 | $1,081 |
| Kaletra | 16 | $14,849 | $928 |
| Invirase | 12 | $13,916 | $1,160 |
| Tenofovir Disoproxil | 45 | $8,918 | $198 |
| Lamivudine-Zidovudine | 21 | $8,823 | $420 |
| Abacavir-Lamivudine | 34 | $7,898 | $232 |
| Norvir | 16 | $6,988 | $437 |
| Nevirapine Er | 15 | $6,957 | $464 |
| Lamivudine | 12 | $2,388 | $199 |
| Nevirapine | 21 | $727 | $35 |
| Dapsone | 11 | $697 | $63 |
| Stavudine | 12 | $461 | $38 |
| Sulfamethoxazole-Trimethoprim | 17 | $123 | $7 |
| Gabapentin | 13 | $100 | $8 |
2017: 37 drugs
| Epclusa | 16 | $414,288 | $25,893 |
| Prezcobix | 154 | $263,418 | $1,711 |
| Zepatier | 12 | $224,937 | $18,745 |
| Genvoya | 59 | $161,917 | $2,744 |
| Truvada | 94 | $148,473 | $1,579 |
| Descovy | 83 | $131,657 | $1,586 |
| Evotaz | 71 | $117,316 | $1,652 |
| Triumeq | 38 | $99,751 | $2,625 |
| Isentress | 69 | $96,235 | $1,395 |
| Atripla | 24 | $61,527 | $2,564 |
| Tivicay | 40 | $61,289 | $1,532 |
| Viread | 57 | $52,441 | $920 |
| Stribild | 16 | $47,962 | $2,998 |
| Edurant | 46 | $45,913 | $998 |
| Complera | 16 | $41,998 | $2,625 |
| Abacavir-Lamivudine | 47 | $28,082 | $597 |
| Reyataz | 19 | $27,817 | $1,464 |
| Kaletra | 27 | $26,594 | $985 |
| Epzicom | 13 | $16,286 | $1,253 |
| Invirase | 12 | $14,390 | $1,199 |
| Nevirapine Er | 30 | $13,767 | $459 |
| Itraconazole | 20 | $13,750 | $687 |
| Norvir | 33 | $11,625 | $352 |
| Lamivudine-Zidovudine | 36 | $11,567 | $321 |
| Entecavir | 22 | $7,235 | $329 |
| Didanosine | 12 | $3,334 | $278 |
| Lamivudine | 12 | $3,079 | $257 |
| Fluconazole | 36 | $2,389 | $66 |
| Rifampin | 22 | $1,437 | $65 |
| Ethambutol | 12 | $995 | $83 |
| Dapsone | 13 | $901 | $69 |
| Nevirapine | 18 | $599 | $33 |
| Valacyclovir | 12 | $525 | $44 |
| Stavudine | 11 | $433 | $39 |
| Isoniazid | 21 | $108 | $5 |
| Sulfamethoxazole-Trimethoprim | 18 | $107 | $6 |
| Hydrochlorothiazide | 19 | $26 | $1 |
2016: 36 drugs
| Harvoni | 30 | $930,027 | $31,001 |
| Prezcobix | 143 | $225,008 | $1,573 |
| Truvada | 116 | $171,211 | $1,476 |
| Evotaz | 71 | $108,833 | $1,533 |
| Atripla | 38 | $90,335 | $2,377 |
| Genvoya | 30 | $78,981 | $2,633 |
| Isentress | 60 | $76,529 | $1,275 |
| Epzicom | 59 | $75,559 | $1,281 |
| Stribild | 24 | $68,721 | $2,863 |
| Complera | 26 | $64,679 | $2,488 |
| Viread | 70 | $61,861 | $884 |
| Triumeq | 24 | $56,641 | $2,360 |
| Tivicay | 25 | $35,929 | $1,437 |
| Edurant | 35 | $31,622 | $903 |
| Kaletra | 32 | $29,911 | $935 |
| Reyataz | 16 | $22,128 | $1,383 |
| Nevirapine Er | 31 | $16,941 | $546 |
| Abacavir-Lamivudine-Zidovudine | 11 | $15,312 | $1,392 |
| Norvir | 46 | $15,060 | $327 |
| Invirase | 12 | $13,739 | $1,145 |
| Rifabutin | 12 | $10,788 | $899 |
| Itraconazole | 19 | $10,605 | $558 |
| Abacavir | 25 | $9,682 | $387 |
| Lamivudine-Zidovudine | 28 | $9,165 | $327 |
| Entecavir | 13 | $6,745 | $519 |
| Lamivudine | 22 | $4,694 | $213 |
| Fluconazole | 31 | $2,416 | $78 |
| Rifampin | 27 | $1,702 | $63 |
| Pyrazinamide | 11 | $1,634 | $149 |
| Ethambutol | 17 | $1,266 | $74 |
| Dapsone | 12 | $801 | $67 |
| Stavudine | 12 | $703 | $59 |
| Valacyclovir | 12 | $561 | $47 |
| Nevirapine | 12 | $396 | $33 |
| Sulfamethoxazole-Trimethoprim | 55 | $365 | $7 |
| Isoniazid | 43 | $222 | $5 |
2015: 38 drugs
| Harvoni | 34 | $1,067,154 | $31,387 |
| Sovaldi | 14 | $388,924 | $27,780 |
| Truvada | 127 | $166,436 | $1,311 |
| Reyataz | 87 | $107,626 | $1,237 |
| Atripla | 48 | $105,876 | $2,206 |
| Prezista | 57 | $72,216 | $1,267 |
| Stribild | 28 | $69,345 | $2,477 |
| Complera | 32 | $67,995 | $2,125 |
| Viread | 66 | $61,739 | $935 |
| Isentress | 50 | $60,388 | $1,208 |
| Kaletra | 64 | $54,814 | $856 |
| Norvir | 156 | $44,861 | $288 |
| Epzicom | 35 | $41,415 | $1,183 |
| Prezcobix | 26 | $37,761 | $1,452 |
| Edurant | 35 | $28,923 | $826 |
| Tivicay | 18 | $23,064 | $1,281 |
| Abacavir | 48 | $19,046 | $397 |
| Evotaz | 11 | $15,607 | $1,419 |
| Nevirapine Er | 21 | $12,880 | $613 |
| Lamivudine-Zidovudine | 24 | $12,663 | $528 |
| Invirase | 12 | $12,627 | $1,052 |
| Entecavir | 16 | $9,754 | $610 |
| Didanosine | 36 | $9,015 | $250 |
| Lamivudine | 29 | $7,825 | $270 |
| Itraconazole | 11 | $7,027 | $639 |
| Moxifloxacin | 13 | $4,481 | $345 |
| Ethambutol | 29 | $2,805 | $97 |
| Rifampin | 37 | $2,771 | $75 |
| Pyrazinamide | 15 | $2,633 | $176 |
| Fluconazole | 14 | $1,759 | $126 |
| Valacyclovir | 15 | $603 | $40 |
| Stavudine | 12 | $473 | $39 |
| Nevirapine | 18 | $444 | $25 |
| Sulfamethoxazole-Trimethoprim | 43 | $167 | $4 |
| Isoniazid | 28 | $153 | $5 |
| Ibuprofen | 13 | $51 | $4 |
| Trazodone | 12 | $48 | $4 |
| Famotidine | 13 | $22 | $2 |
2014: 32 drugs
| Sovaldi | 12 | $342,531 | $28,544 |
| Truvada | 143 | $186,262 | $1,303 |
| Reyataz | 139 | $166,277 | $1,196 |
| Isentress | 76 | $96,163 | $1,265 |
| Prezista | 79 | $94,584 | $1,197 |
| Atripla | 39 | $81,250 | $2,083 |
| Viread | 85 | $74,069 | $871 |
| Epzicom | 64 | $71,992 | $1,125 |
| Complera | 31 | $65,708 | $2,120 |
| Kaletra | 72 | $59,212 | $822 |
| Norvir | 213 | $58,952 | $277 |
| Pegasys | 12 | $39,074 | $3,256 |
| Voriconazole | 14 | $29,601 | $2,114 |
| Edurant | 32 | $24,738 | $773 |
| Tivicay | 19 | $23,702 | $1,247 |
| Lamivudine-Zidovudine | 36 | $22,792 | $633 |
| Abacavir | 50 | $21,185 | $424 |
| Baraclude | 24 | $17,487 | $729 |
| Didanosine | 60 | $16,180 | $270 |
| Viramune Xr | 14 | $8,993 | $642 |
| Lamivudine | 25 | $5,935 | $237 |
| Fluconazole | 26 | $3,071 | $118 |
| Rifampin | 28 | $2,383 | $85 |
| Ethambutol | 20 | $2,000 | $100 |
| Valacyclovir | 16 | $994 | $62 |
| Nevirapine | 32 | $801 | $25 |
| Zidovudine | 11 | $659 | $60 |
| Stavudine | 11 | $633 | $58 |
| Sulfamethoxazole-Trimethoprim | 61 | $439 | $7 |
| Isoniazid | 33 | $191 | $6 |
| Ibuprofen | 12 | $73 | $6 |
| Famotidine | 15 | $66 | $4 |
2013: 32 drugs
| Truvada | 161 | $201,410 | $1,251 |
| Reyataz | 148 | $165,077 | $1,115 |
| Prezista | 114 | $126,937 | $1,113 |
| Isentress | 72 | $78,997 | $1,097 |
| Norvir | 262 | $75,542 | $288 |
| Viread | 84 | $68,743 | $818 |
| Complera | 30 | $59,352 | $1,978 |
| Kaletra | 72 | $56,877 | $790 |
| Atripla | 27 | $52,041 | $1,927 |
| Epzicom | 37 | $38,691 | $1,046 |
| Pegasys | 12 | $32,425 | $2,702 |
| Lamivudine-Zidovudine | 49 | $31,715 | $647 |
| Voriconazole | 13 | $24,727 | $1,902 |
| Viramune Xr | 41 | $24,705 | $603 |
| Abacavir | 46 | $20,187 | $439 |
| Edurant | 26 | $18,984 | $730 |
| Didanosine | 52 | $13,213 | $254 |
| Ribapak | 12 | $9,597 | $800 |
| Baraclude | 20 | $9,265 | $463 |
| Lamivudine | 15 | $2,919 | $195 |
| Nevirapine | 32 | $1,970 | $62 |
| Rifampin | 22 | $1,605 | $73 |
| Valacyclovir | 14 | $1,209 | $86 |
| Stavudine | 12 | $1,121 | $93 |
| Sulfamethoxazole-Trimethoprim | 39 | $316 | $8 |
| Gemfibrozil | 13 | $309 | $24 |
| Acetaminophen-Codeine | 12 | $188 | $16 |
| Isoniazid | 27 | $167 | $6 |
| Famotidine | 25 | $157 | $6 |
| Hydrocodone-Acetaminophen | 11 | $120 | $11 |
| Sertraline | 13 | $82 | $6 |
| Ibuprofen | 13 | $57 | $4 |
Money from drug and device companies
$804 in 2024
| 2024 | 11 | 31 | None | $804 |
| 2023 | 15 | 60 | None | $1,378 |
| 2022 | 11 | 52 | None | $1,315 |
| 2021 | 9 | 48 | $1,200 | $2,289 |
| 2020 | 8 | 40 | None | $1,047 |
| 2019 | 12 | 77 | None | $1,319 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| ViiV Healthcare | Cabenuva | $202 | 8 payments
|
| Gilead Sciences | None | $202 | 7 payments
|
| Merck Sharp & Dohme | Pifeltro | $126 | 5 payments
|
| Abbvie | Mavyret | $85 | 4 payments
|
| Lilly USA | Verzenio | $34 | 1 payment
|
| Qiagen | None | $33 | 1 payment
|
See all 31 published payments
| Incyte | Meals · 2024-09-18 | Jakafi | $28 |
| Gilead Sciences | Meals · 2024-09-03 | None | $31 |
| Abbvie | Meals · 2024-07-31 | Mavyret | $24 |
| Gilead Sciences | Meals · 2024-07-16 | None | $31 |
| ViiV Healthcare | Meals · 2024-07-15 | Rukobia | $18 |
| ViiV Healthcare | Meals · 2024-07-10 | Dovato | $22 |
| Merck Sharp & Dohme | Meals · 2024-07-03 | Dificid | $21 |
| ViiV Healthcare | Meals · 2024-06-26 | Cabenuva | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2024-06-18 | Imfinzi | $19 |
| Gilead Sciences | Meals · 2024-06-17 | None | $24 |
| Merck Sharp & Dohme | Meals · 2024-06-12 | Pifeltro | $24 |
| ViiV Healthcare | Meals · 2024-06-05 | Dovato | $30 |
| ViiV Healthcare | Meals · 2024-05-22 | Cabenuva | $29 |
| Gilead Sciences | Meals · 2024-05-14 | None | $27 |
| Merck Sharp & Dohme | Meals · 2024-05-08 | Pifeltro | $32 |
| Novartis Pharmaceuticals | Meals · 2024-05-07 | Scemblix | $28 |
| Abbvie | Meals · 2024-05-02 | Mavyret | $24 |
| Gilead Sciences | Meals · 2024-04-25 | None | $29 |
| Pharmacosmos Therapeutics | Meals · 2024-04-22 | Monoferric | $25 |
| ViiV Healthcare | Meals · 2024-04-18 | Dovato | $14 |
| ViiV Healthcare | Meals · 2024-04-17 | Dovato | $25 |
| Gilead Sciences | Meals · 2024-04-09 | None | $27 |
| ViiV Healthcare | Meals · 2024-04-03 | Cabenuva | $38 |
| Merck Sharp & Dohme | Meals · 2024-03-27 | Dificid | $18 |
| Mirati Therapeutics | Meals · 2024-03-22 | Krazati | $22 |
| Gilead Sciences | Meals · 2024-03-13 | None | $33 |
| Abbvie | Meals · 2024-03-06 | Mavyret | $15 |
| Merck Sharp & Dohme | Meals · 2024-02-14 | Pifeltro | $30 |
| Qiagen | Meals · 2024-01-25 | None | $33 |
| Abbvie | Meals · 2024-01-10 | Mavyret | $22 |
| Lilly USA | Meals · 2024-01-04 | Verzenio | $34 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $1,378
| Gilead Sciences | None | $437 | 18 payments
|
| ViiV Healthcare | Dovato | $243 | 13 payments
|
| Abbvie | Mavyret | $189 | 8 payments
|
| Merck Sharp & Dohme | Keytruda | $120 | 5 payments
|
| Janssen Biotech | Symtuza | $87 | 4 payments
|
| Theratechnologies | Egrifta | $80 | 3 payments
|
| Pharmacosmos Therapeutics | Monoferric | $30 | 1 payment
|
| Dynavax Technologies | Heplisav-B | $29 | 1 payment
|
| Eisai | Lenvima | $28 | 1 payment
|
| Novartis Pharmaceuticals | Tasigna | $27 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $25 | 1 payment
|
| Mirati Therapeutics | Krazati | $24 | 1 payment
|
| MorphoSys US | Monjuvi | $22 | 1 payment
|
| Seagen | Padcev | $22 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $17 | 1 payment
|
2022: $1,315
| Gilead Sciences | None | $785 | 27 payments
|
| Theratechnologies | Egrifta | $110 | 4 payments
|
| Janssen Biotech | Symtuza | $102 | 6 payments
|
| Abbvie | Mavyret | $75 | 3 payments
|
| ViiV Healthcare | Cabenuva | $63 | 3 payments
|
| Novartis Pharmaceuticals | Kisqali | $60 | 3 payments
|
| Merck Sharp & Dohme | Pifeltro | $34 | 2 payments
|
| Amgen | Nplate | $30 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $24 | 1 payment
|
| Melinta Therapeutics | Kimyrsa | $20 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $12 | 1 payment
|
2021: $2,289
| Gilead Sciences | Epclusa | $1,715 | 20 payments
|
| ViiV Healthcare | Dovato | $169 | 10 payments
|
| Janssen Biotech | Symtuza | $148 | 9 payments
|
| Janssen Products LP | Symtuza | $99 | 1 payment
|
| AbbVie | Mavyret | $41 | 2 payments
|
| Mayne Pharma | None | $40 | 2 payments
|
| Merck Sharp & Dohme | Pifeltro | $38 | 2 payments
|
| Paratek Pharmaceuticals | Nuzyra | $24 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $15 | 1 payment
|
2020: $1,047
| Gilead Sciences | None | $422 | 18 payments
|
| AbbVie | Mavyret | $145 | 6 payments
|
| Janssen Biotech | Prezcobix | $120 | 6 payments
|
| Janssen Products LP | Symtuza | $99 | 1 payment
|
| Mayne Pharma | Doryx | $87 | 1 payment
|
| Merck Sharp & Dohme | Isentress | $79 | 4 payments
|
| ViiV Healthcare | Dovato | $75 | 3 payments
|
| Theratechnologies | Egrifta | $20 | 1 payment
|
2019: $1,319
| Gilead Sciences | None | $400 | 38 payments
|
| Astellas Pharma US | Cresemba | $174 | 4 payments
|
| Merck Sharp & Dohme | Isentress | $154 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $125 | 1 payment
|
| AbbVie | Mavyret | $115 | 7 payments
|
| ViiV Healthcare | Dovato | $110 | 6 payments
|
| Janssen Biotech | Symtuza | $84 | 6 payments
|
| Dynavax Technologies | Heplisav-B | $65 | 1 payment
|
| Vyera Pharmaceuticals | Daraprim 30 Tablet in 1 Bottle | $29 | 2 payments
|
| Theratechnologies | Egrifta | $24 | 1 payment
|
| Novartis Pharmaceuticals | Votrient | $21 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | None | $19 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 78.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1629021662
- Licence
- CA A90570California A90570: Current · expires 2028-06-30
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-05-19
- NPI last updated
- 2024-10-03
- NPI record certified
- 2024-10-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 500 W Hospital Rd, French Camp, CA, 95231
This office lists an electronic records connection.